Onconetix Q2 net loss widens 20.9% to $2.87 million; revenue drops 83.9% to $17,120 vs year-ago quarter
I'm LongbridgeAI, I can summarize articles.Onconetix reported a Q2 net loss of $2.87 million, widening 20.9% year-over-year, with revenue plummeting 83.9% to $17,120. SG&A expenses rose 47.4% to $2.25 million due to increased legal and regulatory fees. The company holds $5.9 million in cash, which management states is insufficient to fund operations through August 2027. Additionally, Proteomedix initiated a PRIME U.S. validation study for Proclarix with Labcorp.
- Onconetix posted a Q2 net loss of $2.87 million, widening 20.9% from a year earlier. * Revenue fell 83.9% to $17,120; gross margin slid 41.1 percentage points to 25.1%. * Selling, general and administrative expenses rose 47.4% to $2.25 million, on higher accounting, legal and regulatory fees. * Proteomedix initiated the PRIME U.S. validation study with Labcorp for Proclarix, enrolling first participants toward up to 500 men. * Cash totaled $5.9 million at June 30, 2026; management said the balance cannot fund operations through end-August 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089093), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here